MULTIBODY Trademark

Trademark Overview


On Friday, October 21, 2016, a trademark application was filed for MULTIBODY with the United States Patent and Trademark Office. The USPTO has given the MULTIBODY trademark a serial number of 79209028. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, November 8, 2024. This trademark is owned by Crescendo Biologics Limited. The MULTIBODY trademark is filed in the Treatment & Processing of Materials Services, Computer & Software Services & Scientific Services, Chemical Products, and Pharmaceutical Products categories with the following description:

Treatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments

Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions,...

Chemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic products

Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design

General Information


Serial Number79209028
Word MarkMULTIBODY
Filing DateFriday, October 21, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, November 8, 2024
Registration Number5450600
Registration DateTuesday, April 24, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 6, 2018

Trademark Statements


Goods and ServicesTreatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments
Goods and ServicesPharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibodies for therapeutic purposes, namely, therapeutic agents for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products
Pseudo MarkMULTI BODY
Goods and ServicesChemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic products
Goods and ServicesScientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 8, 2024
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 8, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 8, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 8, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCrescendo Biologics Limited
Party Type30 - Original Registrant
Legal Entity Type24 - NOT AVAILABLE
AddressCambridge, Cambridgeshire CB22 3AT
GB

Party NameCrescendo Biologics Limited
Party Type20 - Owner at Publication
Legal Entity Type24 - NOT AVAILABLE
AddressCambridge, Cambridgeshire CB22 3AT
GB

Party NameCrescendo Biologics Limited
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressCambridge, Cambridgeshire CB22 3AT
GB

Trademark Events


Event DateEvent Description
Thursday, June 1, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, June 9, 2017APPLICATION FILING RECEIPT MAILED
Thursday, June 22, 2017REFUSAL PROCESSED BY MPU
Friday, June 23, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, December 7, 2017NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, December 12, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, June 5, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 6, 2017ASSIGNED TO EXAMINER
Tuesday, June 13, 2017NON-FINAL ACTION WRITTEN
Wednesday, June 14, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 14, 2017REFUSAL PROCESSED BY IB
Tuesday, December 19, 2017ASSIGNED TO LIE
Thursday, December 21, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 21, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 28, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 17, 2018NOTICE OF PUBLICATION
Thursday, February 1, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 6, 2018PUBLISHED FOR OPPOSITION
Tuesday, April 24, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, July 24, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, February 1, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, September 7, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, April 24, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, October 27, 2023LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Friday, November 8, 2024RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Friday, November 8, 2024CANCELLED SECTION 71
Saturday, August 19, 2023RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Thursday, August 9, 2018FINAL DISPOSITION PROCESSED
Thursday, August 9, 2018FINAL DISPOSITION NOTICE SENT TO IB